Cardiovascular
Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC
July 27, 2010 4:34 am | by Bio-Medicine.Org | News | CommentsMUNDELEIN, Ill. , July 27 /- Sysmex America, Inc., a leading medical diagnostic instrument manufacturer and information systems developer, today announced plans to debut its expanded cell image analysis portfolio during this year's American Association of Clinical Chemistry's (AACC)...
Momenta surges on first drug approval
July 23, 2010 9:36 am | by Mass High Tech: The Journal of New England Technology | News | CommentsMomenta Pharmaceuticals Inc. surged 76 percent in midday trading Friday on the U.S. Food and Drug Administration's approval of its generic version of a blockbuster Sanofi-Aventis drug to treat blood clots.
Lotus Pharmaceuticals Terminates SEDA
July 22, 2010 11:36 am | by Bio-Medicine.Org | News | CommentsBEIJING , July 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has entered into a...
Golden Meditech Announces Annual Results for FY 2009/10
July 22, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsHONG KONG , July 22 /PRNewswire-Asia-FirstCall/ -- China's leading integrated medical enterprise Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," HKEx: 801) is pleased to announce its annual results for the year ended 31 March 2010 . During the reporting period, total...
Huifeng Bio-Pharmaceutical Technology Announces a New Spain Order
July 22, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsXI'AN, China , July 22 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announced the receipt of its...
CardioGenics Holdings Inc. Receives New Ticker Symbol
July 22, 2010 8:33 am | by Bio-Medicine.Org | News | CommentsMISSISSAUGA, Ontario , July 22 /- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company's ticker symbol has...
Sysmex America and Medica Corporation Announce Distribution Partnership
July 22, 2010 8:33 am | by Bio-Medicine.Org | News | CommentsMUNDELEIN, Ill. , July 22 /- Sysmex America, Inc., a leading developer and manufacturer of medical diagnostic instrumentation and information systems, today announced a partnership agreement with Medica Corporation for the exclusive distribution of the EasyCell® assistant to...
Electroactive Polymer Based Cardiac Ablation Catheters For Greater Flexibility
July 21, 2010 12:15 pm | by Strategic Polymer Sciences | Articles | CommentsMapping/ablation catheters are used to treat atrial fibrillation. Current mechanical catheters can be difficult and time consuming to operate and hinder reproducible and consistent ablation. This article describes new electroactive polymer (EAP) technology that provides the basis for the development of electronically controlled steerable actuators. The EAP technology will enable standard catheter platforms to incorporate advanced micro-steerability, reduced procedure times and advanced automation capabilities. The innovative electrically steered catheters will benefit millions of Americans who are suffering from atrial fibrillation.
Zargis Awarded U.S. Army Contract
July 21, 2010 11:32 am | by Bio-Medicine.Org | News | CommentsSTAMFORD, Conn. , July 21 /- Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE ), today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6™ telemedicine systems recently...
ArmaGen® Re-engineers Erythropoietin for Brain Penetration
July 16, 2010 5:35 pm | by Bio-Medicine.Org | News | CommentsLOS ANGELES , July 16 /- Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain...
GTC regains U.S. rights to ATryn blood clot therapeutic
July 16, 2010 7:35 am | by Mass High Tech: The Journal of New England Technology | News | CommentsGTC Biotherapeutics Inc., a developer of drug therapies derived from animal proteins, has regained U.S. commercialization rights to ATryn, a drug intended to prevent blood clots, from Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark.
Merz Aestheticsâ„¢ Ascleraâ„¢ (polidocanol) Injection Now Available in Doctors' Offices Nationwide
July 15, 2010 10:36 am | by Bio-Medicine.Org | News | CommentsSAN MATEO, Calif. , July 15 /- Merz Aesthetics today announced it is now shipping Asclera™ (polidocanol) Injection sclerotherapy treatment to doctors' offices throughout the U.S. Previously only available in Europe , Asclera™ was recently approved by the U.S. Food and...
Cubist drug passes Phase 2 safety test
July 14, 2010 9:45 am | by Mass High Tech: The Journal of New England Technology | News | CommentsCubist Pharmaceuticals Inc. has met its safety objectives in a Phase 2 study of Cubicin, its treatment intended for prosthetic joint infections.
Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions
July 14, 2010 9:45 am | by Bio-Medicine.Org | News | CommentsYINCHUAN, China , July 14 /PRNewswire-Asia/ -- Recently, Xinhua Website reported about Dr. Nie Wentao's nutrition intervention technology for type 1 diabetes mellitus. Dr. Nie Wentao's diabetic treatment technology is becoming a mainstream technology for diabetes treatment, so it aroused...
Helix Bioscience Appointed DNA Drug Sensitivity Testing Distributor for Genelex Corporation
July 14, 2010 9:45 am | by Bio-Medicine.Org | News | CommentsSEATTLE and TULSA, Okla. , July 14 /- Genelex and Helix have announced a personalized prescribing strategic alliance to increase the availability of important new DNA Drug Sensitivity Tests such as Plavitestâ„¢ and Tamoxitestâ„¢. These tests and the GeneMedRx medication management...
Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting
July 13, 2010 8:35 am | by Bio-Medicine.Org | News | CommentsNEWTON, Mass. , July 13 /- Rcadia Medical Imaging today announced that its COR Analyzer® System for the fully automated analysis of coronary CT angiography (cCTA) will be featured in five studies presented at poster sessions during the annual scientific meeting of the Society of...
Early diagnosis key in managing, treating bladder cancer
July 12, 2010 11:36 am | by Baylor College of Medicine | News | CommentsEarly diagnosis of bladder cancer is critical to management and treatment of the disease and improving chances of survival, said a urologic oncologist from Baylor College of Medicine . "Bladder cancer is a highly treatable, highly curable disease particularly before it invades the...
BCM researchers leading efforts in bladder cancer research
July 12, 2010 11:36 am | by Baylor College of Medicine | News | CommentsResearchers from Baylor College of Medicine's Scott Department of Urology , Department of Molecular and Cellular Biology and the NCI-designated Dan L. Duncan Cancer Center are leading major efforts in bladder cancer research, both in the clinical and lab setting. Find out more about...
Older men with smoking history needed for bladder cancer screening study
July 12, 2010 11:36 am | by Baylor College of Medicine | News | CommentsMen over the age of 60 who have smoked for at least 20 years are being asked to participate in a bladder cancer screening study at Baylor College of Medicine . Currently, there is no established screening method for bladder cancer. "We want to find a way to detect the cancer early enough...
Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
July 12, 2010 11:36 am | by Bio-Medicine.Org | News | CommentsPALO ALTO, Calif. , July 12 /- Telik, Inc. (Nasdaq: TELK ) today announced the publication of a review in the journal, Cell Death and Differentiation : Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death;...
Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
July 12, 2010 7:35 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO , PARSIPPANY, N.J. and INDIANAPOLIS , July 12 /- Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of...
Health, Tech Sectors Hasten to Untangle Wireless Issues
July 11, 2010 11:33 pm | by San Diego Business Journal | News | CommentsAn urgent market need to drive down the bloated cost of health care delivery worldwide has spawned a new cooperative spirit among telecommunications, technology and investment companies wanting to develop wireless technology as a way to make health care less expensive and more efficient.
Wireless Firms Reshape Medical Care With Retooled Equipment
July 11, 2010 11:33 pm | by San Diego Business Journal | News | CommentsDue to rapid advancements in the integration of wireless technology and health care, the future of post-hospitalization patient care will soon be coming to a screen nearby: on BlackBerries, iPads and iPhones.
Stereotaxis Announces Second Quarter 2010 Earnings Release Date and Conference Call
July 9, 2010 10:37 am | by Bio-Medicine.Org | News | CommentsST. LOUIS , July 9 /- Stereotaxis, Inc. (Nasdaq: STXS ) announced today that it will release its financial results for the second quarter ended June 30, 2010 , on Monday, August 2, 2010 after the close of the market. The Company will host a conference call and webcast on Monday, August 2,...
Drug Study Shows Improvement in Major Orthopedic Surgery Care
July 9, 2010 5:36 am | by Bio-Medicine.Org | News | CommentsHAMILTON , Canada , July 9, 2010 /- An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being led by a steering committee chaired by McMaster University...
